Reports Q3 revenue $65.3M vs $58.8M last year. “We are pleased to have our previously announced restatement completed,” said Christine Chambers, CFO of PetMeds. “This restatement resulted principally from the correction of accounting treatment for certain prior period sales taxes between mid-2018 through mid-2022. This restatement does not have any impact on our anticipated fiscal 2024 revenue or gross margins or on our cash position as of December 31, 2023. Our team has worked diligently to complete the accounting analysis, and I want to thank all our stakeholders for their trust and patience during this period.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PETS:
- PetMed Express options imply 3.1% move in share price post-earnings
- PetMeds® to Give Away Free Pet Food for a Year to Three Lucky Pet Owners and $1,000 in PetMeds® Credits to Three Local Animal Shelters
- PetMed Express Faces Nasdaq Compliance Challenge
- PetMed Express Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q
- PetMed Express receives notice of non-compliance from Nasdaq
